LifeMap Solutions Emerges to Develop Big Data-Powered Mobile Health Products
LifeMap Solutions Partners with Icahn School of Medicine at Mount Sinai; Leadership Team Includes Deep Biotech and Silicon Valley Experience
ALAMEDA, Calif. – May 07, 2014 – LifeMap Solutions, Inc., a medical technology startup focused on creating innovative mobile health (mHealth) products and services powered by big data, today announced an initial $5 million seed round led by parent company LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., with additional participation via in-kind support from its development partner, the Icahn School of Medicine at Mount Sinai.
Corey Bridges, a Silicon Valley veteran, will serve as LifeMap Solutions’ Chief Executive Officer. Over the past two decades, Bridges has overseen the market introductions of several innovative technology companies, including Netflix, Zone Labs, and The Multiverse Network. A pre-IPO employee at Netscape, he launched several ground-breaking Internet products internationally, and years later launched James Cameron’s CAMERON | PACE Group in China and Europe.
“In the mid-nineties, we saw the intersection of breakthrough technologies and cultural readiness that took the Internet into the mainstream and changed the world,” Bridges said. “A similar intersection of technology and culture is happening now with personal health and big data, where the impact on society may be as profound and as far-reaching as the Internet has been to the world.”
David Warshawsky, Ph.D., Chief Executive Officer of parent company LifeMap Sciences, and cofounder of LifeMap Solutions with Bridges, brings with him more than 20 years of experience in cutting-edge research, development, implementation, and leadership in biotech, pharmaceutical, and bioinformatics industries.
“The medical technology industry is evolving at a faster pace than anyone predicted even five years ago,” Warshawsky said. “These exciting times translate into massive opportunities for innovation. In the years ahead, we intend to apply our industry’s best practices and LifeMap’s key proprietary technology toward creating mHealth products and services that will serve a range of markets.”
LifeMap Solutions is working directly with research scientists at the Icahn School of Medicine at Mount Sinai to develop its technology. As part of the partnership, Mount Sinai’s Eric Schadt, Ph.D. – founding director of the Icahn Institute for Genomics and Multiscale Biology – will lend his research experience and technical expertise to LifeMap Solutions as the newly formed company’s leading science advisor. Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology.
Core members of the LifeMap Solutions team will work closely with Mount Sinai’s world-class research scientists and development personnel. Dr. Schadt said of the partnership, “We’re excited to combine Mount Sinai’s scientific expertise with LifeMap Solutions’ ability to build mobile health application products and services to help people lead healthier lives and contribute to medical research.”
The details of the partnership were managed by Mount Sinai Innovation Partners, which facilitates the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships with industry.
About LifeMap Solutions, Inc.
LifeMap Solutions is developing innovative digital health solutions in partnership with the Icahn Institute for Genomics and Multiscale Biology, which is located within the Icahn School of Medicine at Mount Sinai. LifeMap Solutions integrates health and wellness information with care team guidance into a secure mHealth platform to deliver digital health solutions that empower patients to make better choices to achieve optimal health outcomes. LifeMap Solutions is a subsidiary of BioTime, Inc. LifeMap Solutions is headquartered in San Jose, California. For more information, please visit www.lifemap-solutions.com.
About BioTime, Inc.
BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime’s focus is on pluripotent stem cell technology based on human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime was incorporated in the state of California in 1990 and is a publicly traded company listed on the NYSE MKT stock exchange. The company is headquartered in Alameda, California, with operations in Singapore, China, and Israel. For more information, please see www.biotimeinc.com.
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime’s Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.